

***Following VASCEPA's® FDA approval in December 2019 (and launch in January 2020) for its new cardiovascular risk indication, what percentage of prescriptions for VASCEPA in the United States are for patients with triglyceride (TG) levels  $\geq$  500 mg/dL?***

Data from Symphony Health Patient Longitudinal Claims for the first quarter of 2020 (the three months ended March 31, 2020) indicate that approximately 10.3% of aggregate prescription claims in the United States were for patients with triglyceride (TG) levels  $\geq$ 500 mg/dL. For patients with established cardiovascular disease, approximately 8.6% of VASCEPA® prescriptions were to patients who had TG levels  $\geq$ 500 mg/dL. For patients with a diabetes diagnosis, approximately 12.7% of VASCEPA prescriptions were to patients who had TG levels  $\geq$ 500 mg/dL. Because VASCEPA's label for its cardiovascular risk indication is new, whereas its label for treating patients with TG levels  $\geq$ 500 mg/dL was launched in 2013, it is anticipated that the proportion of patients treated with VASCEPA who have TGs  $\geq$ 500 mg/dL is likely to decline over time as use of VASCEPA is anticipated to grow for its new indication. It is VASCEPA's new indication which is the primary focus of Amarin's current promotion of VASCEPA in the United States.

Currently, generic versions of VASCEPA have not launched and are FDA approved only for the initial indication for VASCEPA (treating patients with TGs  $\geq$ 500 mg/dL). If generic versions of VASCEPA launch and, without license from Amarin, directly or indirectly promote use of such product(s) in a manner that infringes Amarin's intellectual property rights, Amarin intends to vigorously pursue all available legal and regulatory remedies. Success in pursuing potential remedies of this nature, including potentially pursuing litigation, are prone to various uncertainties. We refer you to the risk factors section of our most recent periodic report filed with the SEC on form 10-Q or 10-K for more information related to such forward looking statements and such uncertainties.

Dated October 9, 2020